Estudo randomizado | Benefício de sobrevida global com tebentafuspe no melanoma uveal metastático.
1 Out, 2021 | 18:33h
Comentário no Twitter
Treatment with tebentafusp resulted in longer overall survival than the control therapy among previously untreated patients with metastatic uveal melanoma. https://t.co/HnSdWItKIp pic.twitter.com/qu4huRn3Mu
— NEJM (@NEJM) September 27, 2021